US › Healthcare

Protara Therapeutics Inc (TARA)

US · Healthcare · Biotechnology

$3.70+2.21%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-21.7M

EPS

$-0.36

EPS estimate

$-0.33

EPS came in at -0.36 against a street estimate of -0.33 — a miss of 9.1%.

Key statistics

Market cap

$221.6M

Forward P/E

0.0

P/B

1.44

Book value

$2.73

EPS (TTM)

$-1.30

52-week high

$7.82

52-week low

$3.03

50-day MA

$3.99

200-day MA

$5.06

Beta

1.49

Analyst view

Analysts rate Protara Therapeutics Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $25.71.

Shareholding

Insiders

2.30%

Institutions

78.39%

Largest institutional holders

Fund	Stake
HHG PLC	8.81%
BlackRock Inc	5.74%
Millennium Management LLC	5.25%
Velan Capital Investment Management LP	4.81%
Blackstone Inc	3.83%
Vanguard Capital Management, LLC	3.59%
Sio Capital Management, LLC	3.25%
Integral Health Asset Management, LLC	2.54%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Protara Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.